SUPPLEMENTAL ASCORBATE IN SUPPORTIVE TREATMENT OF CANCER - RE-EVALUATION OF PROLONGATION OF SURVIVAL TIMES IN TERMINAL HUMAN CANCER
SUPPLEMENTAL ASCORBATE IN SUPPORTIVE TREATMENT OF CANCER - RE-EVALUATION OF PROLONGATION OF SURVIVAL TIMES IN TERMINAL HUMAN CANCER
复制标题
DOI：
10.1073/pnas.75.9.4538
复制
发表时间：
1978-01-01
影响因子：
11.1
通讯作者：
PAULING, L
中科院分区：
文献类型：
--
作者：
CAMERON, E;PAULING, L
研究了100名晚期癌症患者的生存时间，这些患者补充了抗坏血酸，通常是10克/天，作为他们日常管理的一部分，以及1000名匹配的对照组，接受了除抗坏血酸以外的相同治疗的类似患者。试验证实，抗坏血酸治疗的患者和匹配的对照组是同一群不可治疗患者的代表性亚群。生存时间不仅从无法治愈的日期开始计算，而且从最终达到晚期的癌症第一次住院的确切已知数据开始计算。接受抗坏血酸治疗的患者平均生存时间比对照组多300天。22%接受抗坏血酸治疗的患者和0.4%的对照组患者在无法治疗的日期后存活时间超过1年。22例接受抗坏血酸治疗的患者在达到明显终末期后的平均生存时间为2.4年；接受抗坏血酸治疗的患者中有8例仍然存活，无法治疗后的平均生存时间为3.5年。
The survival times of 100 terminal cancer patients who were given supplemental ascorbate, usually 10 g/day, as part of their routine management and 1000 matched controls, similar patients who had received the same treatment except for the ascorbate was studied. Tests confirm that the ascorbate-treated patients and the matched controls were representative subpopulations of the same population of untreatable patients. Survival times were measured not only from the date of untreatability but also from the precisely known data of 1st hospital attendance for the cancer that eventually reached the terminal stage. The ascorbate-treated patients were found to have a mean survival time about 300 days greater than that of the controls. Survival times greater than 1 yr after the date of untreatability were observed for 22% of the ascorbate-treated patients and for 0.4% of the controls. The mean survival time of these 22 ascorbate-treated patients is 2.4 yr after reaching the apparently terminal stage; 8 of the ascorbate-treated patients were still alive, with a mean survival time after untreatability of 3.5 yr.